Business
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing Following the DMC review, the study protocol will be updated, and topline results
About this update from Biomx Inc.
[{"type":"image","alt":"BiomX Inc","displaySize":"","headline":null,"caption":"BiomX Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://ml-eu.globenewswire.com/Resource/Download/d2c84a29-3ba3-417f-b71d-e67f2f0d2586?size=2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jb3n6Jt0yeUWy2GsATvlFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://ml-eu.globenewswire.com/Resource/Download/d2c84a29-3ba3-417f-b71d-e67f2f0d2586?size=2","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Jue5re0FRBelq1OgCYxKtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://ml-eu.globenewswire.com/Resource/Download/d2c84a29-3ba3-417f-b71d-e67f2f0d2586?size=2","width":1200,"height":675}},"lazy":false},{"type":"text","content":"The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial","length":220,"tagName":"p"},{"type":"text","content":"An independent Data Monitoring Committee (DMC) completed a safety review following adverse events identified in the BX004 Phase 2b trial and recommended that the study continue with revised dosing","length":196,"tagName":"p"},{"type":"text","content":"Following the DMC review, the study protocol will be updated, and topline results are now expected in Q2 2026","length":109,"tagName":"p"},{"type":"text","content":"NESS ZIONA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the Company’s Phase 2b trial of BX004 in patients with cystic fibrosis. The Company is working with the third-party manufacturer to address recent FDA follow up information requests in order to lift the FDA’s clinical hold with respect to the trial. In parallel, an independent DMC has completed a safety review of the BX004 Phase 2b clinical trial.","length":734,"tagName":"p"},{"type":"text","content":"BiomX recently received additional follow-up questions from the FDA related to the third-pa...